$OPTN
OptiNose, Inc. Stock $optn

$optn Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149465024000018 Filed on March 07, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$14.88M	$19.87M	$70.99M
YoY Change	25.61%	-4.75%	-6.93%
Cost Of Revenue	$1.231M	$2.131M	$8.633M
YoY Change	-27.84%	-28.51%	-6.8%
Gross Profit	$13.65M	$17.73M	$62.35M
YoY Change	34.61%	-0.79%	-6.95%
Gross Profit Margin	91.73%	89.27%	87.84%
Selling, General & Admin	$20.52M	$18.96M	$79.80M
YoY Change	-9.7%	-18.66%	-25.87%
% of Gross Profit	150.33%	106.91%	127.98%
Research & Development	$1.206M	$1.286M	$5.303M
YoY Change	-32.44%	-55.97%	-65.25%
% of Gross Profit	8.84%	7.25%	8.5%
Depreciation & Amortization	$83.00K	$120.0K	$402.0K
YoY Change	15.28%	-9.09%	-24.44%
% of Gross Profit	0.61%	0.68%	0.64%
Operating Expenses	$21.72M	$20.25M	$85.10M
YoY Change	-11.36%	-22.82%	-30.76%
Operating Profit	-$8.075M	-$2.512M	-$22.75M
YoY Change	-43.8%	-69.94%	-59.3%
Interest Expense	$4.970M	-$7.431M	-$12.71M
YoY Change	6.38%	37.69%	-175.47%
% of Operating Profit
Other Income/Expense, Net		-$24.00K	-$24.00K
YoY Change		-98.28%	-98.28%
Pretax Income	-$14.07M	-$9.967M	-$35.48M
YoY Change	-25.36%	-34.21%	-52.58%
Income Tax
% Of Pretax Income
Net Earnings	-$14.07M	-$9.967M	-$35.48M
YoY Change	-25.36%	-34.21%	-52.58%
Net Earnings / Revenue	-94.54%	-50.17%	-49.99%
Basic Earnings Per Share	-$0.12		-$0.32
Diluted Earnings Per Share	-$0.12	-$0.09	-$0.32
COMMON SHARES
Basic Shares Outstanding	112.7M shares	112.3M shares	112.1M shares
Diluted Shares Outstanding	112.6M shares		112.1M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$51.64M	$73.68M	$73.68M
YoY Change	-38.47%	-21.82%	-21.82%
Cash & Equivalents	$51.64M	$73.68M	$73.68M
Short-Term Investments
Other Short-Term Assets	$4.936M	$3.671M	$3.671M
YoY Change	66.7%	28.13%	28.13%
Inventory	$10.32M	$8.052M	$8.052M
Prepaid Expenses
Receivables	$14.23M	$19.93M	$19.93M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$81.12M	$105.3M	$105.3M
YoY Change	-27.68%	-25.02%	-25.02%
LONG-TERM ASSETS
Property, Plant & Equipment	$754.0K	$815.0K	$2.287M
YoY Change	4.43%	2.52%	-29.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.831M	$1.581M	$109.0K
YoY Change	-9.89%	-46.28%	-78.11%
Total Long-Term Assets	$2.585M	$2.396M	$2.396M
YoY Change	-6.14%	-35.9%	-35.9%
TOTAL ASSETS
Total Short-Term Assets	$81.12M	$105.3M	$105.3M
Total Long-Term Assets	$2.585M	$2.396M	$2.396M
Total Assets	$83.71M	$107.7M	$107.7M
YoY Change	-27.16%	-25.3%	-25.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.912M	$3.886M	$3.886M
YoY Change	-69.38%	-26.55%	-26.55%
Accrued Expenses	$30.07M	$42.41M	$42.41M
YoY Change	2.15%	-1.12%	-5.47%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$130.2M	$130.2M
YoY Change	-100.0%	1.28%	1.28%
Long-Term Debt Due		$130.2M
YoY Change		1.28%
Total Short-Term Liabilities	$32.71M	$176.5M	$176.5M
YoY Change	-80.33%	-1.23%	-1.23%
LONG-TERM LIABILITIES
Long-Term Debt	$130.7M	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.065M	$17.81M	$17.81M
YoY Change	161.67%	2745.21%	-19.47%
Total Long-Term Liabilities	$131.7M	$17.81M	$17.81M
YoY Change	32263.14%	2745.21%	-19.47%
TOTAL LIABILITIES
Total Short-Term Liabilities	$32.71M	$176.5M	$176.5M
Total Long-Term Liabilities	$131.7M	$17.81M	$17.81M
Total Liabilities	$182.9M	$194.3M	$194.3M
YoY Change	-3.07%	-3.24%	-3.24%
SHAREHOLDERS EQUITY
Retained Earnings	-$734.4M	-$720.4M
YoY Change	4.36%	5.18%
Common Stock	$635.3M	$633.9M
YoY Change	0.84%	0.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$99.22M	-$86.61M	-$86.61M
YoY Change
Total Liabilities & Shareholders Equity	$83.71M	$107.7M	$107.7M
YoY Change	-27.16%	-25.3%	-25.3%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$14.07M	-$9.967M	-$35.48M
YoY Change	-25.36%	-34.21%	-52.58%
Depreciation, Depletion And Amortization	$83.00K	$120.0K	$402.0K
YoY Change	15.28%	-9.09%	-24.44%
Cash From Operating Activities	-$22.03M	$6.909M	-$20.53M
YoY Change	110.2%	-139.08%	-69.65%
INVESTING ACTIVITIES
Capital Expenditures	$22.00K	$73.00K	$328.0K
YoY Change		2333.33%	420.63%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$22.00K	-$73.00K	-$328.0K
YoY Change		2333.33%	420.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$300.0K
YoY Change			-99.41%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$7.000K	4.000K	300.0K
YoY Change	-95.68%	-99.99%	-99.42%
NET CHANGE
Cash From Operating Activities	-$22.03M	6.909M	-20.53M
Cash From Investing Activities	-$22.00K	-73.00K	-328.0K
Cash From Financing Activities	$7.000K	4.000K	300.0K
Net Change In Cash	-$22.04M	6.840M	-20.56M
YoY Change	113.65%	-79.34%	26.36%
FREE CASH FLOW
Cash From Operating Activities	-$22.03M	$6.909M	-$20.53M
Capital Expenditures	$22.00K	$73.00K	$328.0K
Free Cash Flow	-$22.05M	$6.836M	-$20.86M
YoY Change	110.41%	-138.66%	-69.19%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Interest Expense InterestExpense	19528000	usd
CY2022	us-gaap	Interest Expense InterestExpense	16843000	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001494650
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2022	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2023	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2023	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2023#FairValueAdjustmentOfWarrants
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38241
CY2023	dei	Entity Registrant Name EntityRegistrantName	OPTINOSE, INC.
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	42-1771610
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1020 Stony Hill Road
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Yardley
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19067
CY2023	dei	City Area Code CityAreaCode	267
CY2023	dei	Local Phone Number LocalPhoneNumber	364-3500
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2023	dei	Trading Symbol TradingSymbol	OPTN
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	119300000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	112651740	shares
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Philadelphia, PA
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	73684000	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	94244000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19926000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	33932000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	8052000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	9443000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3671000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2865000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	105333000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	140484000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	815000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	795000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1581000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2943000	usd
CY2023Q4	us-gaap	Assets Assets	107729000	usd
CY2022Q4	us-gaap	Assets Assets	144222000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3886000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5291000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	42411000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	44864000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	130227000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	128575000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	176524000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	178730000	usd
CY2023Q4	optn	Warrant Liability Non Current WarrantLiabilityNonCurrent	17200000	usd
CY2022Q4	optn	Warrant Liability Non Current WarrantLiabilityNonCurrent	21490000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	611000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	626000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	194335000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	200846000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	112399495	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	112399495	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	111492761	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	111492761	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	112000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	111000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	633742000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	628242000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-720376000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-684893000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-84000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-84000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-86606000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-56624000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	107729000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	144222000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	70987000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	76276000	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	93735000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	132172000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-22748000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-55896000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4290000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1211000	usd
CY2023	optn	Grant And Other Income GrantAndOtherIncome	-24000	usd
CY2022	optn	Grant And Other Income GrantAndOtherIncome	-1396000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	2527000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	513000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-35483000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-74833000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.87
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.87
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	112080062	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	112080062	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	85900139	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	85900139	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-35483000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-74833000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-3000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35483000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-74836000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-21772000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8889000	usd
CY2022	optn	Stock Issued During Period Vested Restricted Stock Units StockIssuedDuringPeriodVestedRestrictedStockUnits	94000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	30446000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	554000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-3000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-74833000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-56624000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5201000	usd
CY2023	optn	Stock Issued During Period Vested Restricted Stock Units StockIssuedDuringPeriodVestedRestrictedStockUnits	1000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	299000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-86606000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-35483000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-74833000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	402000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	532000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	5198000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	8877000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4290000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1211000	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1664000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2318000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-14006000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1517000	usd
CY2023	optn	Increase Decreasein Depositsand Other Assets IncreaseDecreaseinDepositsandOtherAssets	-1632000	usd
CY2022	optn	Increase Decreasein Depositsand Other Assets IncreaseDecreaseinDepositsandOtherAssets	-1963000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1285000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2492000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1414000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2723000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3532000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-9005000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20532000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-67651000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	328000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	63000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-328000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-63000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	51086000	usd
CY2023	optn	Proceedsfrom Issuanceof Common Stock Under Employee Stock Purchase Plan ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan	299000	usd
CY2022	optn	Proceedsfrom Issuanceof Common Stock Under Employee Stock Purchase Plan ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan	554000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	94000	usd
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	usd
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	298000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	300000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	51436000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-20560000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-16271000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94244000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110515000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	73684000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94244000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	13174000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	15091000	usd
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	9000	usd
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	4000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	0	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	0	usd
CY2023	optn	Deferred Offering Costs W Ithin Accounts Payableand Accrued Expenses DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses	0	usd
CY2022	optn	Deferred Offering Costs W Ithin Accounts Payableand Accrued Expenses DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses	408000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1068000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	704000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	Organization and Description of Business<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OptiNose, Inc. (the Company) was incorporated in Delaware in May 2010 (inception) and has facilities in Yardley, Pennsylvania and Ewing, New Jersey. The Company's predecessor entity, OptiNose AS, was formed under the laws of Norway in September 2000. In 2010, OptiNose AS became a wholly-owned subsidiary of the Company as part of an internal reorganization. Optinose AS was liquidated in October 2023. During 2022, the Company's board of directors approved the liquidation of Optinose UK, which is expected to be completed in 2024, in order to simplify the corporate structure. </span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's first commercial product, XHANCE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span> (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the Company's proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE was approved by the United States (US) Food and Drug Administration (FDA) in September 2017 for the treatment of nasal polyps in patients 18 years of age or older. XHANCE was made widely available through commercial channels in April 2018. In January 2023, the indication statement for XHANCE was changed from “for the treatment of nasal polyps” to “for the treatment of chronic rhinosinusitis with nasal polyps” to reflect current FDA labeling terminology and not based on new XHANCE clinical trial data.
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	73684000	usd
CY2023Q4	optn	Working Capital WorkingCapital	-71191000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-720376000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</span></div>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of credit risk</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and accounts receivable. The Company generally invests its cash in deposits with high credit quality financial institutions. Additionally, the Company performs periodic evaluations of the relative credit standing of these financial institutions.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Customer and supplier concentration</span></div>The Company has exposure to credit risk in accounts receivable from sales of product. XHANCE is sold to wholesale pharmaceutical distributors and preferred pharmacy network (PPN) partners, who, in turn, sell XHANCE to pharmacies, hospitals and other customers.
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	72432000	usd
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	92988000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2023	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	6962000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	16575000	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	43193047	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	43609730	shares
CY2023Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	17200000	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	17200000	usd
CY2022Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	21490000	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	21490000	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	21490000	usd
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	0	usd
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-4290000	usd
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	17200000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2400000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1691000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	3281000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	5010000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2371000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2742000	usd
CY2023Q4	us-gaap	Inventory Gross InventoryGross	8052000	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	9443000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5679000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5360000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4864000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4565000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	815000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	795000	usd
CY2023	us-gaap	Depreciation Depreciation	400000	usd
CY2022	us-gaap	Depreciation Depreciation	530000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1472000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2445000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	911000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1971000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	611000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	625000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1522000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2596000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y1M17D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0641
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1053000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	436000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	205000	usd
CY2023Q4	optn	Lessee Operating Lease Liability Payments Due Thereafter LesseeOperatingLeaseLiabilityPaymentsDueThereafter	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1694000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	172000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1522000	usd
CY2023	optn	Operating Lease Cost For Extension OperatingLeaseCostForExtension	0	usd
CY2023	us-gaap	Lease Cost LeaseCost	2122000	usd
CY2022	us-gaap	Lease Cost LeaseCost	2985000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	2368000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	2570000	usd
CY2023Q4	optn	Accrued Product Allowances Current AccruedProductAllowancesCurrent	20145000	usd
CY2022Q4	optn	Accrued Product Allowances Current AccruedProductAllowancesCurrent	27993000	usd
CY2023Q4	optn	Accrued Selling Generaland Administrative Current AccruedSellingGeneralandAdministrativeCurrent	6229000	usd
CY2022Q4	optn	Accrued Selling Generaland Administrative Current AccruedSellingGeneralandAdministrativeCurrent	3799000	usd
CY2023Q4	optn	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	644000	usd
CY2022Q4	optn	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	1298000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	6801000	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	7888000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	4666000	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3015000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1915000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	41500000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	42893000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	911000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1971000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	911000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1971000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	42411000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	44864000	usd
CY2023	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	1
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	873000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1112000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	115000	usd
CY2023Q4	us-gaap	Purchase Obligation PurchaseObligation	0	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000	shares
CY2023Q4	optn	Vote Per Share VotePerShare	1	vote
CY2023	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2022Q4	optn	Class Of Warrant Or Right Restriction Common Shares Maximum Ownership If Exercised Percent ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipIfExercisedPercent	0.0499
CY2022Q4	optn	Class Of Warrant Or Right Restriction Common Shares Maximum Ownership Prior To Execution Percent ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipPriorToExecutionPercent	0.0999
CY2022Q4	optn	Class Of Warrant Or Right Restriction Common Shares Maximum Ownership After Effective Waiting Period Percent ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipAfterEffectiveWaitingPeriodPercent	0.1999
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9364070	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.88
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y18D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2373677	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.64
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	2365346	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	9.87
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	844775	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.47
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8527626	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.03
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M18D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4560096	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.81
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y9M14D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2373677	shares
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5201000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8877000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-35483000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-72750000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-2083000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-35483000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-74833000	usd
CY2023Q4	optn	Deferred Tax Assets Financing Costs DeferredTaxAssetsFinancingCosts	3408000	usd
CY2022Q4	optn	Deferred Tax Assets Financing Costs DeferredTaxAssetsFinancingCosts	3377000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	88166000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	83376000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	118778000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.015
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.008
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.007
CY2023	optn	Effective Income Tax Rate Reconciliation Foreign Operations Impact Percent EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent	-0.092
CY2022	optn	Effective Income Tax Rate Reconciliation Foreign Operations Impact Percent EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent	-0.145
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.006
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.026
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.029
CY2023	optn	Effective Income Tax Rate Reconciliation Foreign Exchange Other Percent EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent	-0.004
CY2022	optn	Effective Income Tax Rate Reconciliation Foreign Exchange Other Percent EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent	-0.017
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.059
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.029
CY2023	optn	Effective Income Tax Rate Reconciliation Prepaid Royalty Write Off Percent EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent	0
CY2022	optn	Effective Income Tax Rate Reconciliation Prepaid Royalty Write Off Percent EffectiveIncomeTaxRateReconciliationPrepaidRoyaltyWriteOffPercent	-0.118
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.071
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.124
CY2023	optn	Effective Income Tax Rate Reconciliation Gain Loss On Warrants EffectiveIncomeTaxRateReconciliationGainLossOnWarrants	0.025
CY2022	optn	Effective Income Tax Rate Reconciliation Gain Loss On Warrants EffectiveIncomeTaxRateReconciliationGainLossOnWarrants	-0.007
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	3544000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	5144000	usd
CY2023Q4	optn	Deferred Tax Assets Interest Expense DeferredTaxAssetsInterestExpense	15540000	usd
CY2022Q4	optn	Deferred Tax Assets Interest Expense DeferredTaxAssetsInterestExpense	14304000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	5291000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	7193000	usd
CY2023Q4	optn	Deferred Tax Assets Leasing Arrangement DeferredTaxAssetsLeasingArrangement	369000	usd
CY2022Q4	optn	Deferred Tax Assets Leasing Arrangement DeferredTaxAssetsLeasingArrangement	642000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2460000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2460000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	116496000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	153000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	171000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	357000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	605000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	510000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	776000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	118268000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	115720000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2487000	usd
CY2023	optn	Deferred Tax Assets Tax Credit Carryforwards Research Term DeferredTaxAssetsTaxCreditCarryforwardsResearchTerm	P20Y
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2548000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd

Files In Submission

Name	View Source	Status
0001494650-24-000018-index-headers.html	Edgar Link	pending
0001494650-24-000018-index.html	Edgar Link	pending
0001494650-24-000018.txt	Edgar Link	pending
0001494650-24-000018-xbrl.zip	Edgar Link	pending
auditorconsentex2312023.htm	Edgar Link	pending
descriptionofsecuritiesex4.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
firstamendmentandwaivertot.htm	Edgar Link	pending
formindemnificationagreeme.htm	Edgar Link	pending
listofsubsidiariesex2112023.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
optinoseincincentivecompen.htm	Edgar Link	pending
optn-20231231.htm	Edgar Link	pending
optn-20231231.xsd	Edgar Link	pending
optn-20231231_g1.jpg	Edgar Link	pending
optn-20231231_g2.jpg	Edgar Link	pending
optn-20231231_g3.jpg	Edgar Link	pending
optn-20231231_g4.jpg	Edgar Link	pending
optn-20231231_g5.jpg	Edgar Link	pending
optn-20231231_g6.jpg	Edgar Link	pending
optn-20231231_g7.jpg	Edgar Link	pending
optn-20231231_g8.jpg	Edgar Link	pending
optn-20231231_g9.jpg	Edgar Link	pending
optn12-31x202310xkex311.htm	Edgar Link	pending
optn12-31x202310xkex312.htm	Edgar Link	pending
optn12-31x202310xkex321.htm	Edgar Link	pending
optn12-31x202310xkex322.htm	Edgar Link	pending
optn-20231231_cal.xml	Edgar Link	unprocessable
optn-20231231_def.xml	Edgar Link	unprocessable
optn-20231231_lab.xml	Edgar Link	unprocessable
optn-20231231_pre.xml	Edgar Link	unprocessable
optn-20231231_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OPTN
OptiNose, Inc. Stock $optn

2024 Q1 Form 10-K Financial Statement

#000149465024000018 Filed on March 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPTN OptiNose, Inc. Stock $optn

2024 Q1 Form 10-K Financial Statement

#000149465024000018 Filed on March 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPTN
OptiNose, Inc. Stock $optn